Clinical trials for Extranodal nasal NK/T cell lymphoma
24 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07380984PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06966154A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLFudan University
- RECRUITINGPhase 2NCT07000617A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaPeking University Cancer Hospital & Institute
- RECRUITINGPhase 1NCT06732492RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ENROLLING BY INVITATIONNCT07450040Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell LymphomaEye & ENT Hospital of Fudan University
- RECRUITINGPHASE1, PHASE2NCT06559553"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCLMingzhi Zhang
- RECRUITINGPhase 2NCT06824883Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaPeking Union Medical College Hospital
- RECRUITINGPHASE1, PHASE2NCT06376721Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaBeijing Tongren Hospital · PI: Liang Wang, M.D.
- RECRUITINGPhase 2NCT06314334Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell LymphomaFudan University · PI: Rong Tao, MD
- RECRUITINGNCT06362148Circulating Tumor DNA in Peripheral T-cell LymphomasUniversity of Aarhus · PI: Francesco A d'Amore, MD, DMSc
- RECRUITINGN/ANCT06069830PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell LymphomaRuijin Hospital
- RECRUITINGN/ANCT05662540PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell LymphomaRuijin Hospital
- RECRUITINGPhase 2NCT05833893Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell LymphomaChinese PLA General Hospital · PI: Yu Zhao, Graduate
- RECRUITINGPhase 2NCT05477264Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal TypeWon Seog Kim
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05627856A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLSichuan Baili Pharmaceutical Co., Ltd. · PI: Wenyu Li, PHD
- RECRUITINGPhase 2NCT04417166Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · PI: Stefano Luminari, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04414163A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeImmuneOncia Therapeutics Inc. · PI: Won Seog Kim
- RECRUITINGPhase 3NCT04365036A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)Sun Yat-sen University
- ACTIVE NOT RECRUITINGPhase 2NCT04127227Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal TypeSun Yat-sen University
- ACTIVE NOT RECRUITINGPhase 2NCT03728972Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeMemorial Sloan Kettering Cancer Center · PI: Alison Moskowitz, MD
- RECRUITINGPhase 2NCT02859402Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell LymphomasKeimyung University Dongsan Medical Center
- RECRUITINGPhase 2NCT02974647Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaMemorial Sloan Kettering Cancer Center · PI: Alison Moskowitz, MD
- RECRUITINGPhase 1NCT01555892Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEBaylor College of Medicine · PI: Helen E Heslop, MD
- ACTIVE NOT RECRUITINGPhase 1NCT00336063Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell LymphomaNational Cancer Institute (NCI) · PI: Wen-Son Hsieh